Pharma BD Deal Intelligence
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment with LB2102.
First-in-human Phase 1 (NCT05680922) of LB2102, the DLL3-targeted autologous CAR-T licensed to Novartis, in r/r SCLC/LCNEC: ORR 20% (4/20) and DCR 70% overall;…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis licensed Legend Biotech's DLL3-targeting CAR-T cell therapies including LB2102, with Novartis gaining exclusive worldwide development and commercialization rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Legend Biotech Corporation (this deal) | 2023 | $1.1B | 69 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2023 deals · Novartis AG deals · Gene Therapy deals